Emergex’s vaccines are advantageous in numerous ways:
- Potentially reduce viral disease to subclinical by priming a T-cell mediated immune response.
- They are not developed to induce an antibody response (are self-adjuvanted and limit or eliminate the allergic, autoimmune or antibody mediated side effects associated with the traditional vaccines).
- They are 100% synthetic and do not contain any RNA or DNA – do not use inactivated or live-attenuated pathogens – and therefore should be inherently safer to develop and use.
- They replicate the cellular immune responses to highly conserved recognition elements of the pathogen often present in internal proteins in which selective pressure for mutation is minimal. An advantage of this approach is that these internal components are conserved within viral strains of the same family, making a universal vaccine to tackle highly mutagenic viruses such as seasonal flu possible.
- They are designed to be delivered by novel microneedle technologies (for example a skin patch) which means that there is less need for primary health care providers to administer the vaccines, no need for travel to central health clinics, hence improving compliance – a major challenge to providing vaccination in developing settings. Future planned dry patches are stable at room temperature avoiding the need for refrigeration, which enables easy transportation to the remote parts of the world where they are needed the most.